Table 2

NS6S and GM1 antibody associations

NNS6S+GM1+NS6S+ or GM1+
All MN serums75324332434864
Axon loss only30124013431757
Sensory loss, legs28134612431864
SNAPs abnormal164259561063
Paraspinous den11655764873
IgM M-protein+171271148217100
IgM M-protein–55193515272851
Sensory PN561221001221
  • IgM binding to NS6S and GM1 ganglioside were similarly common in motor neuropathy patients. They were occasionally present, or absent, in other disease control patient groups. They were more common in motor neuropathy patients with IgM M-proteins (p=0.0001) but were similarly common in groups with and without motor conduction block.

  • %+, per cent of patients tested positive; ALS, amyotrophic lateral sclerosis; CIDP, chronic immune demyelinating polyneuropathy; GM1+, patients with high titres (≥2000) of serum IgM binding to GM1 ganglioside; IgM M-protein+, IgM M-protein present in serum detected by immunofixation methodology; IgM M-protein–, IgM M-protein not found in serum by immunofixation methodology; IVIg, intravenous immunoglobulin; MN, motor neuropathy; N, number of patients; N+, number of patients positive; NS6S+, patients with high titres (≥7000) of serum IgM binding to NS6S disaccharide; Paraspinous den, denervation found on EMG in thoracic paraspinous muscles; Sensory PN, sensory polyneuropathy; SNAPs abnormal, sensory nerve action potentials absent or reduced amplitude.